INM - InMed Pharmaceuticals Inc

INM - InMed Pharmaceuticals Inc

https://www.inmedpharma.com

Recent News

Powered by Alpha Vantage

Cognition Therapeutics Shares Jump 12% After Hours Following Encouraging Phase 2 Alzheimer's Trial Data - Cognition Therapeutics ( NASDAQ:CGTX ) , InMed Pharmaceuticals ( NASDAQ:INM )

Benzinga • 2 months, 1 week ago • score: 0.07

Cognition Therapeutics Inc CGTX rose 12.10% to $0.45 during after hours on Thursday, following a surge of 20.82% gain during regular hours. What Happened: The hike in Cognition Therapeutics' stock price is attributed to the promising results from its Alzheimer's drug, Zervimesine.

Why InMed's Alzheimer's Drug Candidate Is Fueling Sudden Stock Surge - InMed Pharmaceuticals ( NASDAQ:INM )

Benzinga • 2 months, 3 weeks ago • score: 0.01

INM-901 reduced IL-6, IL-1β, KC/Gro, and IL-2 in an LPS-induced neuroinflammation model. Trading volume hit 6.63 million shares Tuesday, well above the 1.31 million average. Get access to the leaderboards pointing to tomorrow's biggest stock movers. InMed Pharmaceuticals Inc.

Why InMed Pharmaceuticals ( INM ) Stock Is Skyrocketing - InMed Pharmaceuticals ( NASDAQ:INM )

Benzinga • 7 months, 3 weeks ago • score: 0.13

InMed Pharmaceuticals shares are trading higher by 45% during Tuesday's session. The company announced that INM-901 reduced Alzheimer 's-related inflammation in a preclinical study.

InMed Reports Encouraging Data For Its Cannabinoid INM-089 In Treating Dry AMD, An Ocular Disease With Rising Patient Numbers As National Population Ages - InMed Pharmaceuticals ( NASDAQ:INM )

Benzinga • 1 year ago • score: 0.26

When it comes to diseases of the eyes, age-related macular degeneration or AMD is a big one, afflicting 19.8 million people or 12.6% of Americans aged 40 and older. In adults 50+ it is the most common cause of severe loss of eyesight.

Why Keysight Technologies Shares Are Trading Higher By Around 11%; Here Are 20 Stocks Moving Premarket - Keysight Techs ( NYSE:KEYS )

Benzinga • 1 year ago • score: -0.06

Shares of Keysight Technologies, Inc. KEYS rose sharply in today's pre-market trading after the company reported stronger-than-expected results for its third quarter.

Interval:

EMA1: EMA2:

AI Tools

Key Metrics

Trend: Downtrend

Source: Snapshot

InMed Pharmaceuticals Inc., a clinical-stage pharmaceutical company, researches and develops cannabinoid-based therapies. The company is headquartered in Vancouver, Canada.

52W High

$7.16

52W Low

$1.72

MA Status:

50D: Below 200D: Below

Beta (~1 neutral, <0.9 lower risk)

0.41

Valuation

As of 2025-03-31 (Overview)

Trailing P/E (<15 better)

N/A

Forward P/E (<15 better)

N/A

EV/EBITDA (<8 favorable)

1.00

EV/Revenue (<3 favorable)

0.08

P/S (TTM) (<3 favorable)

0.86

P/B (<3 favorable)

0.60

Ownership

Retail‑heavy

Source: Overview

Insiders (1–5% typical)

0.34%

Institutions (25–75% balanced)

6.24%

Shares Outstanding

2,002,200

Float

1,204,300

Dividend Yield (2–6% sweet spot)

N/A

Ex‑Dividend Date

N/A

Income & Growth

Profitability: Weak

As of 2025-03-31 (Overview)

Revenue (TTM)

4,921,000

Gross Profit (TTM)

1,596,000

EPS (TTM)

-11.65

Profit Margin (>10% good)

-1.69%

Operating Margin (TTM) (higher better)

-1.68%

ROE (TTM) (>15% strong)

-0.92%

EPS YoY (Quarterly) (>10% good)

N/A

Revenue YoY (Quarterly) (>8% good)

0.08

Momentum

Value

N/A

Previous

N/A

Trend

—

Signal Cross

No cross

As of

—